Comment Re: How this may play out (Score 1) 72
The real issue is that the packaging process used to create vaccines in quantity is a process where you mix a tank of mRNA with a tank of other stuff and get a tank of lipid nanoparticles. Getting different mRNA in each dose means you only get one patient's vaccine per time you start and stop the machine. There's also a step where one copy of mRNA is used to make a macroscopic quantity of copies in a bioreactor that needs to be flushed in between different sequences, but can just run when making enough of the same thing for a large population. It's likely that the cost for each different sequence will come down if it's worth designing and building equipment that switches every dose, but there's an intermediate time between proving that the treatment is useful and being able to provide it in a cost-effective way.